Sugi Predict

Sugi Predict / Compounds / SCHEMBL782992

SCHEMBL782992

SCHEMBL782992

Cn1c(=O)oc2ccc(-c3cncc(F)c3C=O)cc21

nearest known ligand 0.44

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ GPR55 Q9Y2T6 3/20 0.44
▸ CYP11B2 P19099 1/20 0.40
▸ KCNJ1 P48048 8/20 0.38
▸ CREBBP Q92793 1/20 0.35
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ DDB1 Q16531 1/20 0.34
▸ CRBN Q96SW2 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ PDE10A Q9Y233 1/20 0.34
▸ SCD5 Q86SK9 1/20 0.34
▸ TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL782527 0.81 GPR55 (0.43) GPR55CYP11B2KCNJ1CREBBPSCD5
SCHEMBL742976 0.79 GPR55 (0.41) GPR55CYP11B2KCNJ1MEN1KMT2A
SCHEMBL782507 0.76 CYP11B2 (0.48) GPR55CYP11B2KCNJ1DDB1CRBN
SCHEMBL801469 0.75 GPR55 (0.54) GPR55CYP11B2KCNJ1DDB1CRBN
SCHEMBL783391 0.74 CYP11B2 (0.45) GPR55CYP11B2KCNJ1MEN1KMT2A
SCHEMBL782504 0.71 CYP11B2 (0.47) GPR55CYP11B2KCNJ1MEN1KMT2A
SCHEMBL783451 0.71 GPR55 (0.40) GPR55CYP11B2KCNJ1SCD5
SCHEMBL744470 0.70 GPR55 (0.44) GPR55CYP11B2KCNJ1CREBBP
SCHEMBL782551 0.70 CYP11B2 (0.40) GPR55CYP11B2KCNJ1CREBBPSCD5
SCHEMBL782752 0.69 GPR55 (0.52) GPR55CYP11B2KCNJ1CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430018-B1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS NOVARTIS AG (CH) 2013-07-03 — — EP disclosed
EP-2430018-B1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS NOVARTIS AG (CH) 2013-07-03 — — EP disclosed
US-8455522-B2 Benzoxazolone derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2013-06-04 — — US disclosed
US-8455522-B2 Benzoxazolone derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2013-06-04 — — US disclosed
US-8455522-B2 Benzoxazolone derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2013-06-04 — — US disclosed
US-20120071514-A1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 — — US disclosed
US-20120071514-A1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 — — US disclosed
US-20120071514-A1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071514-A1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS CYP11B2, CYP11B1, CYP21A2 GPR55 852/4885CYP11B2 1/4885KCNJ1 630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.